Equities

Australian Clinical Labs Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ACL:ASX

Australian Clinical Labs Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)2.58
  • Today's Change-0.150 / -5.49%
  • Shares traded1.03m
  • 1 Year change-30.46%
  • Beta1.3568
Data delayed at least 20 minutes, as of Feb 06 2026 05:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Australian Clinical Labs Limited is a private provider of pathology services. Its laboratories perform a range of pathology tests each year for a range of clients, including doctors, specialists, patients, hospitals, and corporate clients. It performs a range of services for doctors, patients and corporate clients, including chemical pathology, hematology, histopathology & cytopathology, serology & microbiology, allergy & immunology, molecular cancer testing, genetic carrier screening & other antenatal testing, cardiac testing services, veterinary pathology, functional pathology, and pathology services for clinical trials, among others. Its specialist services include molecular cancer services, obstetrics and gynecology, pharmacogenetic testing, gastroenterology, and hospital services. It has operations in Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory. Its SunDoctors brand provides skin cancer care services.

  • Revenue in AUD (TTM)741.27m
  • Net income in AUD32.43m
  • Incorporated2020
  • Employees4.70k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ACL:ASX since
announced
Transaction
value
Healius LtdRumoured13 Feb 202513 Feb 2025Rumoured-29.12%--
Data delayed at least 20 minutes, as of Feb 06 2026 05:10 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Apiam Animal Health Ltd206.92m832.00k160.98m--230.771.3211.820.7780.00380.00381.110.66130.8094.5715.75--0.33781.650.38961.9366.2263.460.41751.970.50262.330.458671.371.1111.83-83.13-27.2927.960.3129
Eureka Group Holdings Ltd45.79m20.06m211.16m42.009.780.873910.284.610.05060.05060.11890.56640.1506--206.26--6.606.126.756.2954.7652.7543.8137.02----0.190830.2211.3013.0451.9019.9021.256.71
Monash IVF Group Ltd271.92m25.01m270.80m892.0010.901.105.680.99590.06380.06380.69470.63210.54333.439.15304,839.705.134.126.324.8489.1689.429.447.690.53216.080.418295.496.6513.34483.1516.3613.965.80
Australian Clinical Labs Ltd741.27m32.43m524.76m4.70k15.693.103.110.70790.1740.1743.900.88121.277.9010.16157,716.805.6212.058.8418.5382.7081.444.438.790.48264.880.62855.616.458.6135.50-4.70-2.16--
Artrya Ltd28.00k-16.41m534.32m----18.00--19,083.00-0.1782-0.17820.00030.18780.0013--0.006---76.86-50.54-84.04-53.79-----58,592.86-224,202.80----0.0285-------17.19--76.21--
Australian Unity Ltd2.56bn29.28m577.02m7.70k----5.650.2253--------0.2504------0.28630.2535--------1.141.08--2.320.3517--19.2212.82225.8526.26-3.12--
Healius Ltd1.34bn-563.00m668.04m8.00k--1.14--0.497-0.7754-0.20821.850.80960.56486.947.21168,025.00-23.66-7.07-30.32-8.6784.0885.70-41.88-14.730.49780.00310.608--5.69-2.9015.97---7.13--
Integral Diagnostics Ltd627.22m4.67m928.59m3.03k207.671.3415.131.480.0120.0122.021.860.577913.4923.69207,343.800.4440.37460.49590.420295.5295.190.76830.6680.65952.130.4574568.8933.7017.91107.70-27.3118.22-7.07
Regis Healthcare Ltd1.16bn48.95m2.01bn11.00k41.34--20.391.730.16110.16113.82-0.05550.5928--46.38--2.50-0.2222---2.22----4.22-0.4523--------14.5211.37328.58--17.0932.18
Data as of Feb 06 2026. Currency figures normalised to Australian Clinical Labs Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

66.31%Per cent of shares held by top holders
HolderShares% Held
Allan Gray Australia Pty Ltd.as of 22 Sep 202532.83m17.08%
Colonial First State Investments Ltd.as of 11 Sep 202514.31m7.45%
Superannuation Funds Management Corp. of South Australiaas of 11 Sep 202514.11m7.34%
First Sentier Investors RQI Pty Ltd.as of 15 Oct 202511.14m5.79%
Vinva Investment Management Ltd.as of 26 Sep 202510.13m5.27%
Investors Mutual Ltd.as of 26 Sep 20259.96m5.18%
Australian Ethical Investments Ltd. (Investment Management)as of 21 Jan 20269.57m4.98%
Yarra Funds Management Ltd.as of 02 Oct 20249.46m4.92%
Regal Funds Management Pty Ltd.as of 06 Aug 20258.95m4.66%
The Vanguard Group, Inc.as of 07 Jan 20267.00m3.64%
More ▼
Data from 31 Jul 2025 - 28 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.